finasteride has been researched along with Local Neoplasm Recurrence in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, HU; Arya, M; Day, E; Dobbs, C; Dudderidge, T; Emberton, M; Fiorentino, F; McCracken, S; Prevost, AT; Reddy, D; Shah, TT; Staffurth, J; Sydes, M; Winkler, M | 1 |
| Juan, YS; Lee, HY; Li, CC; Wang, CS; Wu, WJ | 1 |
| Pienta, KJ; Reyes, DK | 1 |
| Bañez, LL; Blake, GW; Crawford, ED; McLeod, DG; Moul, JW | 1 |
| Kujala, PM; Murtola, TJ; Tammela, TL | 1 |
| Tisman, G | 1 |
| Barqawi, AB; Crawford, ED; Handel, L; Moul, JW; Ziada, A | 1 |
| Hellerstedt, B | 1 |
| Ferrari, AC; McCarron, JP; Mencher, SK; Wang, LG | 1 |
| Andriole, G; Boake, R; Crawford, D; DeKernion, J; Kadmon, D; Lieber, M; Rajfer, J; Schroeder, F; Smith, J; Soloway, M | 1 |
| Andriole, GL; Bhayani, SB | 1 |
| Broering, JM; Carroll, PR; Grossfeld, GD; Latini, D; Lubeck, DP; Small, EJ | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
3 review(s) available for finasteride and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Tosyl Compounds; Treatment Outcome | 2003 |
Hormonal manipulation for rising PSA after radical prostatectomy.
Topics: Androgen Antagonists; Anilides; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds | 1999 |
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Disease Progression; Drug Administration Schedule; Finasteride; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Orchiectomy; Postoperative Complications; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Treatment Outcome | 2001 |
5 trial(s) available for finasteride and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial.
Topics: Ablation Techniques; Androgen Antagonists; Anilides; Brachytherapy; Costs and Cost Analysis; Equivalence Trials as Topic; Finasteride; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Progression-Free Survival; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Research Design; Tosyl Compounds; United Kingdom | 2020 |
Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Finasteride; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2009 |
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Flutamide; Follow-Up Studies; Humans; Life Tables; Male; Neoplasm Recurrence, Local; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Radioisotope Teletherapy; Survival Analysis; Treatment Outcome | 2003 |
Treatment with finasteride following radical prostatectomy for prostate cancer.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms | 1995 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
5 other study(ies) available for finasteride and Local Neoplasm Recurrence
| Article | Year |
|---|---|
5α-reductase inhibitors impact prognosis of urothelial carcinoma.
Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma; Carcinoma, Transitional Cell; Cholestenone 5 alpha-Reductase; Dutasteride; Finasteride; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Hyperplasia; Receptors, Androgen; Taiwan; Urothelium | 2020 |
Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds | 2021 |
High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Cohort Studies; Disease-Free Survival; Dutasteride; Finasteride; Finland; Humans; Kallikreins; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Sulfonamides; Survival Rate; Tamsulosin | 2013 |
Unusual anti-angiogenic effect of combined hormonal blockade.
Topics: Aged; Angiogenesis Inhibitors; Anilides; Antineoplastic Agents, Hormonal; Capillaries; Chemotherapy, Adjuvant; Drug Therapy, Combination; Finasteride; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Skin; Telangiectasis; Tosyl Compounds; Treatment Outcome | 2002 |
The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Drug Synergism; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Tumor Cells, Cultured | 2004 |